A 2026 review argues that neurovascular-unit dysfunction may precede amyloid-beta generation in Alzheimer’s disease and then synergize with amyloid deposition, tau pathology, inflammation, and neuronal loss.1 The model is vascular biology plus amyloid biology: blood vessels, barrier integrity, and amyloid deposition can amplify each other early enough to affect dementia risk and progression. Research Highlights …
A 2026 medicinal-chemistry study found that thymol carbamate TC-6 inhibited human butyrylcholinesterase at 3.6 nM, showed more than 2,500-fold selectivity over human acetylcholinesterase, crossed a blood-brain-barrier screening assay, and improved spatial-memory behavior in amyloid-β-injected mice. Research Highlights TC-6 hit BuChE hard: Wu et al. reported human butyrylcholinesterase (BuChE) inhibition at 3.6 nM, compared with 9,320 …
A 2026 ADNI/A4 validation study found that Alzheimer’s plasma-biomarker machine-learning models still ranked amyloid PET status well across cohorts, but the practical rule-out number moved hard: negative predictive value fell from 0.831 inside ADNI to 0.644 when the ADNI-trained model was applied to A4.1 Research Highlights 1,707-person ADNI/A4 test: researchers trained amyloid PET prediction models …
Lecanemab blood biomarkers may rebound much faster than amyloid PET after treatment stops: a 2026 PK/PD model estimated that half of the Aβ42/40 treatment effect is lost within 0.5 years, compared with 12.1 years for amyloid PET signal.1 Research Highlights 0.5-year rebound for Aβ42/40: Bhagunde et al. estimated that half of the Aβ42/40 treatment effect …
A 2026 TADPOLE modeling study reported that a sequential neural process with normalizing flows predicted future Alzheimer diagnostic stage with mAUC 0.965 ± 0.006, ahead of the authors’ earlier sequential-neural-process model at 0.937 ± 0.014.1 The result is a strong benchmark signal for uncertainty-aware disease-progression AI, but it is still retrospective modeling evidence rather than …
A 2026 ALZAN memory-clinic cohort found that cerebrospinal-fluid alpha-synuclein seed amplification assay detected 19 of 20 Lewy body dementia cases, with 95% sensitivity and 93.5% specificity against non-Lewy-body, non-Alzheimer’s controls.1 The same assay was positive in 32 of 203 Alzheimer’s disease patients, which makes the result a co-pathology warning as much as a diagnostic win. …
A 2026 multi-cohort Alzheimer’s disease study found that MRI radiomics from the hippocampus and amygdala linked plasma pTau217 and smell identification to cognitive impairment — with more added cognitive signal than simple regional volume. The result is useful because it points to a possible bridge between blood biomarkers and brain-circuit damage, but it is still …